MODESTO, Calif., May 8 /PRNewswire/ -- NeuroPro Technologies, Inc. and Pipeline Biomedical Holdings, LLC announce that they have signed an agreement to develop and commercialize a rapid test for detecting cerebrospinal fluid. The agreement forms a new company, Pipeline-Neuro, LLC, which will exist specifically for the purpose of accomplishing this goal. Development will begin immediately.
“An accurate, rapid test for detecting cerebrospinal fluid (CSF) has been needed in the healthcare marketplace for a long time,” says Robert Cohen, President and CEO of Pipeline-Neuro, LLC. He stated, “Such a test will help emergency room doctors and neurosurgeons rapidly detect CSF leaks that can lead to dangerous infections in the brain or spine.” Each year in the United States, over 1 million people are treated and released from hospital emergency departments with traumatic head injuries. An additional 230,000 people are hospitalized with traumatic head injuries. 2 to 3% of head injuries will result in the occurrence of CSF leaks.
NeuroPro founder and practicing neurosurgeon Benjamin J. Remington, MD, said, “Determining whether there is a CSF leak is a critical point in the diagnosis of a head injury. A quick and accurate answer helps the patient get the right treatment immediately and can help avoid unnecessary expenses.” Current methods of positively identifying CSF take two days to two weeks for results, during which time the doctor may admit the patient and needlessly treat them for a CSF leak.
NeuroPro Technologies, Inc. was formed in 2002 and is based in Modesto, California. The principal founders are practicing neurosurgeons. The company’s mission is to alleviate human suffering by creating truly innovative solutions to neuro-related issues.
Pipeline Biomedical Holdings, LLC was formed in 2007 and is based in Parsippany, New Jersey. The company concentrates on medical product and technology development. Pipeline Biomedical takes concepts from its earliest phases through the initial market release while proving its commercial viability.
Contact: John I Green Cell: 209.345.1856 Email: jgreen@neuroprotech.com Website: http://www.neuroprotech.com
This release was issued through eReleases(TM). For more information, visit http://www.ereleases.com.
NeuroPro Technologies, Inc.
CONTACT: John I Green of NeuroPro Technologies, Inc., +1-209-345-1856,jgreen@neuroprotech.com
Web site: http://www.neuroprotech.com//
